A Phase IIb Study of OligoG in Subjects With Cystic Fibrosis

PHASE2CompletedINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

January 31, 2017

Study Completion Date

September 30, 2017

Conditions
Cystic Fibrosis
Interventions
DRUG

alginate oligosaccharide

Inhalation

Trial Locations (18)

2100

Rigshospitalet, Copenhagen

13353

Pediatric Pulmonology and Immunology, Charité Universitätsmedizin, Berlin

14186

Stockholm CF-center, Karolinska Universitetssjukhuset, Stockholm

30625

Klinik für Pneumologie, CF-Ambulanz, Hanover

41345

CF-mottagningen, Sahlgrenska Universitetssjukhuset, Gothenburg

50924

CF Zentrum Köln, Universitätskrankenhaus Köln, Cologne

60590

Medizinische Klinik I, Pneumologie, Uniklinik, Frankfurt

72076

Center for Pediatric Clinical Studies,, Tübingen

80336

Mukoviszidose-Zentrum für Erwachsene, Med. Klinik V-Innenstadt (LMU), Münich

81241

Pneumologische Praxis Pasing, Münich

0424

Oslo University Hospital, Oslo

BT9 7AB

Regional Respiratory Centre, Belfast City Hospital, Belfast

CB23 3RE

Papworth Hospital, Cambridge

G4 0SF

Bio-Images Research Ltd, Basement Medical Block, Within GRI, Glasgow

L14 3PE

Liverpool Heart and Chest Hospital, Liverpool

SW3 6NP

Royal Brompton and Harefield NHS Foundation Trust, London

NG7 2UH

Queens Medical Centre, Nottingham

Unknown

Southampton General Hospital, Southampton

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Eurostars

OTHER

collaborator

Smerud Medical Research International AS

OTHER

lead

AlgiPharma AS

INDUSTRY

NCT02157922 - A Phase IIb Study of OligoG in Subjects With Cystic Fibrosis | Biotech Hunter | Biotech Hunter